Cargando…

Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical

BACKGROUND: Clinical progression of Parkinson’s disease (PD) is highly heterogeneous, and its predictors are generally lacking. Identifying predictors of early disease progression is important for patients’ management and follow-up. The current study aims to identify clinical, neuroimaging and bioch...

Descripción completa

Detalles Bibliográficos
Autores principales: Helmy, Asmaa, Hamid, Eman, Salama, Mohamed, Gaber, Ahmed, El-Belkimy, Mahmoud, Shalash, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760567/
https://www.ncbi.nlm.nih.gov/pubmed/35068922
http://dx.doi.org/10.1186/s41983-022-00445-1
_version_ 1784633348908384256
author Helmy, Asmaa
Hamid, Eman
Salama, Mohamed
Gaber, Ahmed
El-Belkimy, Mahmoud
Shalash, Ali
author_facet Helmy, Asmaa
Hamid, Eman
Salama, Mohamed
Gaber, Ahmed
El-Belkimy, Mahmoud
Shalash, Ali
author_sort Helmy, Asmaa
collection PubMed
description BACKGROUND: Clinical progression of Parkinson’s disease (PD) is highly heterogeneous, and its predictors are generally lacking. Identifying predictors of early disease progression is important for patients’ management and follow-up. The current study aims to identify clinical, neuroimaging and biochemical baseline predictors of motor progression in patients with PD. Forty-five PD patients were assessed at baseline, 6 months and 1 year using MDS-UPDRS total and subscores, Hoehn and Yahr (H&Y), Schwab and England (S&E), International Physical Activity Questionnaire (IPAQ). Baseline New Freezing of Gait Questionnaire (NFOG-Q), Berg Balance Scale (BBS), Ten-Meter Walking Test (10-MWT), and Time Up and Go Test (TUG), Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory (BDI), PD questionnaire 39 (PDQ-39), MRI brain, uric acid, lipid profile and glycated hemoglobin were performed. RESULTS: Significant worsening of MDS-UPDRS total, part III scores, H&Y, S&E and IPAQ (p < 0.001) was detected. One-year progression of H&Y and S&E were significantly correlated to disease duration (p = 0.014, p = 0.025, respectively). Progression of H&Y was correlated to baseline TUG (p = 0.035). S&E progression was correlated to baseline MDS-UPDRS total score (rho = 0.478, p = 0.001) and part III (rho = 0.350, p = 0.020), H&Y (rho = 0.401, p = 0.007), PIGD (rho = 0.591, p < 0.001), NFOG-Q (rho = 0.498, p = 0.001), and TUG (rho = 0.565, p = 0.001). Using linear regression, there was no predictors of clinical progression among the used baseline variables. CONCLUSION: Despite the significant motor and physical activity progression over 1 year that was correlated to baseline motor and gait severity, but without predictive value, further similar and longitudinal studies are warranted to detect predictors of early progression and confirm findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41983-022-00445-1.
format Online
Article
Text
id pubmed-8760567
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87605672022-01-18 Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical Helmy, Asmaa Hamid, Eman Salama, Mohamed Gaber, Ahmed El-Belkimy, Mahmoud Shalash, Ali Egypt J Neurol Psychiatr Neurosurg Research BACKGROUND: Clinical progression of Parkinson’s disease (PD) is highly heterogeneous, and its predictors are generally lacking. Identifying predictors of early disease progression is important for patients’ management and follow-up. The current study aims to identify clinical, neuroimaging and biochemical baseline predictors of motor progression in patients with PD. Forty-five PD patients were assessed at baseline, 6 months and 1 year using MDS-UPDRS total and subscores, Hoehn and Yahr (H&Y), Schwab and England (S&E), International Physical Activity Questionnaire (IPAQ). Baseline New Freezing of Gait Questionnaire (NFOG-Q), Berg Balance Scale (BBS), Ten-Meter Walking Test (10-MWT), and Time Up and Go Test (TUG), Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory (BDI), PD questionnaire 39 (PDQ-39), MRI brain, uric acid, lipid profile and glycated hemoglobin were performed. RESULTS: Significant worsening of MDS-UPDRS total, part III scores, H&Y, S&E and IPAQ (p < 0.001) was detected. One-year progression of H&Y and S&E were significantly correlated to disease duration (p = 0.014, p = 0.025, respectively). Progression of H&Y was correlated to baseline TUG (p = 0.035). S&E progression was correlated to baseline MDS-UPDRS total score (rho = 0.478, p = 0.001) and part III (rho = 0.350, p = 0.020), H&Y (rho = 0.401, p = 0.007), PIGD (rho = 0.591, p < 0.001), NFOG-Q (rho = 0.498, p = 0.001), and TUG (rho = 0.565, p = 0.001). Using linear regression, there was no predictors of clinical progression among the used baseline variables. CONCLUSION: Despite the significant motor and physical activity progression over 1 year that was correlated to baseline motor and gait severity, but without predictive value, further similar and longitudinal studies are warranted to detect predictors of early progression and confirm findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41983-022-00445-1. Springer Berlin Heidelberg 2022-01-15 2022 /pmc/articles/PMC8760567/ /pubmed/35068922 http://dx.doi.org/10.1186/s41983-022-00445-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Helmy, Asmaa
Hamid, Eman
Salama, Mohamed
Gaber, Ahmed
El-Belkimy, Mahmoud
Shalash, Ali
Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title_full Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title_fullStr Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title_full_unstemmed Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title_short Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical
title_sort baseline predictors of progression of parkinson’s disease in a sample of egyptian patients: clinical and biochemical
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760567/
https://www.ncbi.nlm.nih.gov/pubmed/35068922
http://dx.doi.org/10.1186/s41983-022-00445-1
work_keys_str_mv AT helmyasmaa baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical
AT hamideman baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical
AT salamamohamed baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical
AT gaberahmed baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical
AT elbelkimymahmoud baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical
AT shalashali baselinepredictorsofprogressionofparkinsonsdiseaseinasampleofegyptianpatientsclinicalandbiochemical